Of note, the time spent in the center was not affected by AMPH or MDMA treatment in a genotype-dependent manner and the reduction in center time seen following Shank1 deletion might reflect a mild increase in anxiety levels and is consistent with the literature (Hung et al., 2008; Silverman et al., 2011). This evidence concerns the gene SHANK1 and Anxiety.